Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 43rd European Bone Marrow Transplant Congress (EBMT) Annual Meeting will be held in Marseilles, France on March 26-29, 2017.

This will also be the 33rd EBMT Nurses Group meeting, 16th EBMT Data Management Group Meeting, 9th EBMT Quality Management Group Meeting, 2nd EBMT Pharmacist Day, and 11th EBMT Patient & Family Day.

EBMT 2017

26–29 March 2017 | Marseille, France

EBMT 2017

26–29 March 2017 | Marseille, France

The 43rd European Bone Marrow Transplant Congress (EBMT) Annual Meeting will be held in Marseilles, France on March 26-29, 2017.

This will also be the 33rd EBMT Nurses Group meeting, 16th EBMT Data Management Group Meeting, 9th EBMT Quality Management Group Meeting, 2nd EBMT Pharmacist Day, and 11th EBMT Patient & Family Day.

Only the beginning of precision medicine and multiple myeloma. 1:24
Only the beginning of precision medicine and multiple myeloma.
Irene Ghobrial • 26 Mar 2017
Predicting and preventing clonal evolution in multiple myeloma 1:47
Predicting and preventing clonal evolution in multiple myeloma
Irene Ghobrial • 26 Mar 2017
Concerns about using social media in oncology 4:58
Concerns about using social media in oncology
Naveen Pemmaraju • 26 Mar 2017
Allogeneic transplant is not the quintessential treatment for ALL anymore! 4:01
Allogeneic transplant is not the quintessential treatment for ALL anymore!
Sebastian Giebel • 26 Mar 2017
Advantages of chemotherapy and hypomethylating agents in myelodysplastic syndrome 3:14
Advantages of chemotherapy and hypomethylating agents in myelodysplastic syndrome
Maria Teresa Voso • 26 Mar 2017
Cellular therapy: a key part of EBMT 2017 1:26
Cellular therapy: a key part of EBMT 2017
Nicolaus Kröger • 26 Mar 2017
Updates on treatment methods for Hodgkin Lymphoma 2:00
Updates on treatment methods for Hodgkin Lymphoma
Stephen Robinson • 26 Mar 2017
Autologous stem cell transplantations: BEAM or BEAC? 2:05
Autologous stem cell transplantations: BEAM or BEAC?
Stephen Robinson • 26 Mar 2017
Treatment methods in mantle cell lymphoma 1:24
Treatment methods in mantle cell lymphoma
Stephen Robinson • 26 Mar 2017
How can clinicians and nurses care for patients with oral graft-versus-host disease (GvHD)? 6:43
How can clinicians and nurses care for patients with oral graft-versus-host disease (GvHD)?
Nathaniel Treister • 27 Mar 2017
What are the differences in health technology assessment (HTA) across Europe? 3:26
What are the differences in health technology assessment (HTA) across Europe?
Jean-Luc Harousseau • 28 Mar 2017
Can the cytomegalovirus be predicted by ELISpot assays? 2:40
Can the cytomegalovirus be predicted by ELISpot assays?
Roy Chemaly • 26 Mar 2017
Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)? 2:36
Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)?
John Gribben • 26 Mar 2017
Is double autologous transplantation in multiple myeloma superior in the age of new agents? 3:44
Is double autologous transplantation in multiple myeloma superior in the age of new agents?
Jean-Luc Harousseau • 28 Mar 2017
Waldenström’s macroglobulinemia: Treatment methods and clonal evolution 1:50
Waldenström’s macroglobulinemia: Treatment methods and clonal evolution
Irene Ghobrial • 27 Mar 2017
Highlights from the EBMT 2017 cell therapy day 2:19
Highlights from the EBMT 2017 cell therapy day
Christian Chabannon • 28 Mar 2017

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals